Clinical trials: Subjects With Type 2 Diabetes Mellitus.
Diabetes Mellitus
Efficacy of Alogliptin and With Pioglitazone in Patients With Type 2 Diabetes.
The purpose of this study is to compare the efficacy of Alogliptin, once daily (QD), taken by itself and with pioglitazone on postprandial lipid measures in type 2 diabetes.
- Trial name
- NCT00655863
- Testing
- Alogliptin and Pioglitazone, Alogliptin
- Where
- 2 sites in Netherlands, Sweden
- Volunteers
- 71 people
- Sponsor
- Takeda
Diabetes, Diabetes Mellitus, Type 1
Evaluating the Use of Two Different Needles in Subjects With Diabetes
This trial is conducted in Europe. The aim of this trial is to compare two needle types when used with a disposable insulin injection pen in the everyday life setting of an insulin treated patient with diabetes.
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Delivery Systems
- Trial name
- NCT00569426
- Testing
- NovoFine® needle 6 mm, NovoFine® needle 8 mm
- Where
- 10 sites in United Kingdom
- Volunteers
- 119 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 2
Comparison of Liraglutide and Glimepiride on Blood Sugar Control in Subjects With Type 2 Diabetes
This trial is conducted in Europe. The aim of this trial is to establish the dose response relationship on glycaemic control of five dose levels of NNC90-1170.
- Trial name
- NCT01509755
- Testing
- liraglutide, glimepiride
- Where
- 29 sites in Denmark, Norway and 2 more
- Volunteers
- 196 people
- Sponsor
- Novo Nordisk A/S
Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Evaluate Safety of Technosphere® Insulin (TI) in Diabetic Subjects With Moderate Obstructive Pulmonary Disease
Examine the effects of TI in combination with an anti-diabetic regimen including inhaled insulin versus anti-diabetic treatment without inhaled insulin on lung function \& pulmonary safety
- Conditions
- Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus, Moderate Chronic Obstructive Pulmonary Disease, Asthma
- Trial name
- NCT00642616
- Testing
- Technosphere® Insulin, Usual Care
- Where
- 21 sites in United States, Russia and 1 more
- Volunteers
- 34 people
- Sponsor
- Mannkind Corporation
Diabetes Mellitus, Non-Insulin-Dependent
Evaluation of the Effect on Glucose Control of AC2993 in Patients With Type 2 Diabetes Mellitus
This is a multicenter, randomized, blinded, placebo-controlled study to assess the effects on glucose control of AC2993 as compared to placebo in patients with type 2 diabetes.
- Trial name
- NCT00035984
- Testing
- AC2993
- Where
- 100 sites in United States
- Volunteers
- 734 people
- Sponsor
- AstraZeneca
Type 2 Diabetes Mellitus, Healthy Volunteers
The Effects of Short-time High-intensity Interval Training on Tissue Glucose and Fat Metabolism in Healthy Subjects and Patients With Type 2 Diabetes
The objectives of this study are to investigate the effects of short-time high-intensity interval training on tissue glucose and fat metabolism in healthy lean subjects and type 2 diabetic patients using modern and noninvasive…
- Trial name
- HITPET (NCT01344928)
- Testing
- HIT exercise intervention, Aerobic exercise intervention
- Where
- Finland
- Volunteers
- healthy volunteers welcome
- Sponsor
- Turku University Hospital
Diabetic Nephropathies
Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy
To assess a new drug, BAY94-8862 given orally at different doses, to evaluate whether it was safe and can help the well being of patients with type 2 diabetes and diabetic nephropathy.
- Trial name
- ARTS-DN (NCT01874431)
- Testing
- Finerenone (BAY94-8862)
- Where
- 147 sites in United States, Australia and 21 more
- Volunteers
- 823 people
- Sponsor
- Bayer
Type 2 Diabetes
Safety and Efficacy Study of Subjects That Are Taking Saxagliptin Added Onto Metformin XR Compared to Subjects Taking Metformin XR Alone
This protocol will compare 24 hour glucose control for subject taking saxagliptin and metformin extended release (XR) versus metformin XR alone
- Trial name
- NCT00683657
- Testing
- Saxagliptin
- Where
- 27 sites in United States, Argentina and 6 more
- Volunteers
- 93 people
- Sponsor
- AstraZeneca
Diabetes, Diabetes Mellitus, Type 2
A Randomised Controlled Clinical Trial in Type 2 Diabetes Comparing Semaglutide to Placebo and Liraglutide
This trial was conducted in Europe,Asia and Africa. Study participants were randomised evenly to treatment with semaglutide (0.1 mg QW - 1.6 mg QW, 6 treatment arms, placebo or liraglutide (1.2 mg QD, or 1.8 mg QD).Treatment…
- Trial name
- NCT00696657
- Testing
- semaglutide, liraglutide
- Where
- 77 sites in Austria, Bulgaria and 12 more
- Volunteers
- 415 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 2
Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes
This trial is conducted globally. The aim of the trial is to investigate efficacy in controlling glycaemia with Victoza® (liraglutide) as add-on to metformin background treatment vs.
- Trial name
- LIRA-PRIME (NCT02730377)
- Testing
- liraglutide, alpha-glucosidase inhibitors, DPP-4 inhibitors
- Where
- 232 sites in United States, Canada and 8 more
- Volunteers
- 1,991 people
- Sponsor
- Novo Nordisk A/S
Obesity, Overweight
Dose-ranging Study to Evaluate the Efficacy, Safety, and Tolerability of AMG 133 in Adult Subjects With Overweight or Obesity, With or Without Type 2 Diabetes Mellitus
The study aims to compare and assess the dose response of 3 selected doses of maridebart cafraglutide compared with placebo, on inducing and maintaining weight loss from baseline at Week 52 in participants with overweight or…
- Conditions
- Obesity, Overweight, Type 2 Diabetes Mellitus
- Trial name
- NCT05669599
- Testing
- Maridebart Cafraglutide
- Where
- 78 sites in United States, Australia and 10 more
- Volunteers
- 592 people
- Sponsor
- Amgen
Diabetes, Diabetes Mellitus, Type 2
Safety and Tolerability of Liraglutide in Japanese Subjects With Type 2 Diabetes
This trial is conducted in Japan. The aim of this trial is to assess the safety after multiple s.c. (subcutaneously) doses of liraglutide in Japanese subjects with type 2 diabetes.
- Trial name
- NCT01615978
- Testing
- liraglutide
- Where
- Japan
- Volunteers
- 15 people
- Sponsor
- Novo Nordisk A/S
Metabolism and Nutrition Disorder, Obesity
Effect of Liraglutide on Body Weight in Overweight or Obese Subjects With Type 2 Diabetes: SCALE™ - Diabetes
This trial is conducted in Africa, Asia, Europe and the United States of America (USA). The aim of this trial is to investigate the potential of liraglutide to induce and maintain weight loss in overweight or obese subjects with…
- Trial name
- NCT01272232
- Testing
- liraglutide
- Where
- 161 sites in United States, France and 11 more
- Volunteers
- 846 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 2
Comparison of NN5401 With Insulin Glargine in Insulin Naive Subjects With Type 2 Diabetes
This trial is conducted in Japan. The aim of this trial is to investigate the efficacy and safety of NN5401 (insulin degludec/insulin aspart) with insulin glargine in subjects with type 2 diabetes in Japan.
- Trial name
- BOOST™ (NCT01272193)
- Testing
- insulin degludec/insulin aspart, insulin glargine
- Where
- 50 sites in Japan
- Volunteers
- 296 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 2
Efficacy and Safety of Basal-bolus Therapy, Comparing Stepwise Addition of Insulin Aspart Versus Complete Basal-bolus Regimen
This trial is conducted in Europe, and North and South America. The aim of this clinical trial is to investigate if the two treatments are equally effective.
- Trial name
- Full STEP™ (NCT01165684)
- Testing
- insulin aspart, insulin detemir
- Where
- 67 sites in United States, Argentina and 5 more
- Volunteers
- 401 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2, Hypoglycemia
FreeStyle Libre 2 Discharge Trial
The goal of this clinical trial is to learn about the benefits of using aa Continuous Glucose Monitoring (CGM) system in patients with diabetes following discharge from the hospital.
- Trial name
- NCT05822232
- Testing
- FreeStyle Libre 2 CGM, FreeStyle Libre Pro blinded CGM, FreeStyle Precision Neo blood glucose meter
- Where
- 2 sites in United States
- Volunteers
- 100 people
- Sponsor
- Palo Alto Medical Foundation
Type 2 Diabetes Mellitus
Trial to Evaluate the Efficacy on Glycemic Variability and Safety of Gemigliptin Compared With Dapagliflozin Added on Metformin Alone or Diabetes Medication Naïve Patient in Type 2 Diabetes Mellitus (Stable II Study)
The objective of this study is to evaluate the efficacy on glycemic variability and safety of gemigliptin 50 mg orally administered once daily for 12 weeks compared with Dapagliflozin 10mg in patients with type 2 diabetes…
- Trial name
- NCT03202563
- Testing
- Gemigliptin 50mg, Dapagliflozin 10mg, Diet/exercise questionnaire
- Where
- South Korea
- Volunteers
- 71 people
- Sponsor
- LG Chem
Type 2 Diabetes Mellitus
Evaluate the Efficacy and Safety of Saxagliptin Added to Insulin Monotherapy or to Insulin Combined With Metformin in Chinese Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control
A Multicenter, Randomized, Double-Blind, Phase 3b Trial to Evaluate the Efficacy and Safety of Saxagliptin Added to Insulin Monotherapy or to Insulin in Combination with Metformin in Chinese Subjects in China with Type 2 Diabetes…
- Trial name
- NCT02104804
- Testing
- Saxagliptin 5mg
- Where
- 11 sites in China
- Volunteers
- 953 people
- Sponsor
- AstraZeneca
Diabetes, Diabetes Mellitus, Type 1
Bioequivalence of Two NovoLog® Formulations in Subjects With Type 1 Diabetes
This trial is conducted in the United States of America (USA). The aim of this trial is to evaluate the clinical performance of two formulations of insulin aspart (NovoLog®) in subjects with type 1 diabetes.
- Trial name
- NCT01464099
- Testing
- insulin aspart
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 1
Comparison of Biphasic Human Insulin 30 With Biphasic Insulin Aspart in Subjects With Diabetes
This trial is conducted in Europe. The aim of this trial is to compare the glycaemic control of biphasic insulin aspart (BIAsp) 70 and/or BIAsp 50 with biphasic human insulin (BHI) 30 treatment.
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- NCT01520818
- Testing
- biphasic insulin aspart 50, biphasic insulin aspart 70, biphasic human insulin 30
- Where
- 77 sites in Belgium, France and 3 more
- Volunteers
- 666 people
- Sponsor
- Novo Nordisk A/S
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.